Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Australia
0
South Africa
0
Listed Dossiers
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 1-((2r,3r)-3-(4-(4-cyanophenyl)-1,3-thiazol-2-yl)-2-(2,5-difluorophenyl)-2-hydroxybutyl)-4-((1rs)-1-((methyl(3-((((methylamino)acetyl)oxy)methyl)pyridin-2-yl)carbamoyl)oxy)ethyl)-1h-1,2,4-triazol-4-ium Monosulfate
2. 4-(2-((2r,3r)-3-(2,5-difluorophenyl)-3-hydroxy-4-(1h-1,2,4-triazol-1-yl)butan-2-yl)-1,3-thiazol-4-yl)benzonitrile
3. Ak-1820
4. Ak1820
5. Bal 4815
6. Bal 8557
7. Bal-4815
8. Bal-8557
9. Bal-8557-002
10. Bal4815
11. Bal8557
12. Bal8557-002
13. Cresemba
14. Isavuconazole
1. 946075-13-4
2. Cresemba
3. Isavuconazonium (sulfate)
4. Bal-8557-002
5. Isavuconazonium Sulfate [usan]
6. Chebi:85977
7. Ak1820
8. 31q44514jv
9. Ak-1820
10. Bal8557-002
11. [2-[1-[1-[(2r,3r)-3-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-2-(2,5-difluorophenyl)-2-hydroxybutyl]-1,2,4-triazol-4-ium-4-yl]ethoxycarbonyl-methylamino]pyridin-3-yl]methyl 2-(methylamino)acetate;hydrogen Sulfate
12. 1-((2r,3r)-3-(4-(4-cyanophenyl)-1,3-thiazol-2-yl)-2-(2,5-difluorophenyl)-2-hydroxybutyl)-4-((1rs)-1-((methyl(3-((((methylamino)acetyl)oxy)methyl)pyridin-2-yl)carbamoyl)oxy)ethyl)-1h-1,2,4-triazol-4-ium Monosulfate
13. Glycine, N-methyl-, (2-(((1-(1-((2r,3r)-3-(4-(4-cyanophenyl)-2-thiazolyl)-2-(2,5-difluorophenyl)-2-hydroxybutyl)-4h-1,2,4-triazolium-4-yl)ethoxy)carbonyl)methylamino)-3-pyridinyl)methyl Ester, Sulfate (1:1)
14. Isavuconazonium Sulfate (usan)
15. 1-((2r,3r)-3-(4-(4-cyanophenyl)thiazol-2-yl)-2-(2,5-difluorophenyl)-2-hydroxybutyl)-4-(1-((methyl(3-(((methylglycyl)oxy)methyl)pyridin-2-yl)carbamoyl)oxy)ethyl)-1h-1,2,4-triazol-4-ium Hydrogen Sulfate
16. Unii-31q44514jv
17. Chembl3137333
18. Dtxsid901026216
19. Ex-a1786
20. Isavuconazonium Sulfate [jan]
21. Akos030527357
22. Isavuconazonium Sulfate [who-dd]
23. Ac-31126
24. As-35043
25. Hy-100373
26. Cs-0018702
27. Isavuconazonium Sulfate [orange Book]
28. D10643
29. A900138
30. Q27158829
31. (2-{[(1-{1-[(2r,3r)-3-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-2-(2,5-difluorophenyl)-2-hydroxybutyl]-1h-1,2,4-triazol-4-ium-4-yl}ethoxy)carbonyl](methyl)amino}pyridin-3-yl)methyl N-methylglycinate Hydrogen Sulfate
| Molecular Weight | 814.8 g/mol |
|---|---|
| Molecular Formula | C35H36F2N8O9S2 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 17 |
| Rotatable Bond Count | 15 |
| Exact Mass | 814.20147343 g/mol |
| Monoisotopic Mass | 814.20147343 g/mol |
| Topological Polar Surface Area | 273 Ų |
| Heavy Atom Count | 56 |
| Formal Charge | 0 |
| Complexity | 1290 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Treatment of invasive aspergillosis, Treatment of mucormycosis
Treatment of Candida infections
Antifungal Agents
Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)
European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38964
Submission : 2023-10-04
Status : Active
Type : II
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : Complete
Rev. Date : 2023-11-08
Pay. Date : 2023-09-28
DMF Number : 38781
Submission : 2023-09-22
Status : Active
Type : II
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39823
Submission : 2024-04-30
Status : Active
Type : II
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36974
Submission : 2022-05-06
Status : Active
Type : II
Honour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.
GDUFA
DMF Review : Complete
Rev. Date : 2024-02-12
Pay. Date : 2024-01-05
DMF Number : 38784
Submission : 2023-09-30
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2024-06-28
Pay. Date : 2024-06-13
DMF Number : 38251
Submission : 2023-03-31
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2024-04-25
Pay. Date : 2024-03-07
DMF Number : 38502
Submission : 2023-10-19
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2024-01-26
Pay. Date : 2023-12-13
DMF Number : 39151
Submission : 2023-12-18
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2025-01-16
Pay. Date : 2024-12-31
DMF Number : 39496
Submission : 2024-03-28
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2024-09-25
Pay. Date : 2024-08-28
DMF Number : 39012
Submission : 2023-11-10
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]About the Company : Transo-Pharm is a licensed distributor of pharmaceutical components for human and veterinary markets. The company supports the full API life cycle, from development to sales, and a...
About the Company : Virupaksha Organics, founded in 2003, is a leading manufacturer of APIs and intermediates. Its FDA-audited, ISO-certified facilities in Kazipally and Pashamylaram produce high-qual...
European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.
About the Company : Polpharma API, a division of a leading Polish pharmaceutical group, has over 75 years of expertise in process development and cGMP manufacturing. Based at an FDA-approved site in C...
ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
About the Company : ChemWerth, established in 1982, is a US-headquartered full-service generic API company. It supplies cGMP-quality APIs to regulated markets worldwide, with exclusive partnerships fo...
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
About the Company : Biophore, founded in 2007, develops and manufactures niche and complex pharmaceutical products. With USFDA- and EU-approved API facilities, a dedicated intermediates site and an R&...
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing APIs, including hard-to-find drug substances, for pharmaceutical and biotech industries. LGM also operates as a full-service drug product ...
Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.
About the Company : Transo-Pharm, founded in 1987, is a fully licensed global distributor of pharmaceutical components for health and veterinary industries. It supports customers throughout the API li...
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...
About the Company : HRV Pharma is a global manufacturer, seller, and exporter of APIs, intermediates, pellets, food-grade chemicals, food additives, and food ingredients. The company provides sourcing...
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
About the Company : Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square meters of R&D centers in...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Cresemba (Isavuconazonium Sulfate) is a small molecule drug, which is currently being evaluated in Approved FDF clinical studies for the treatment of invasive pulmonary aspergillosis.
Lead Product(s): Isavuconazonium Sulfate,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Cresemba
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Pfizer Inc
Deal Size: $226.0 million Upfront Cash: $3.0 million
Deal Type: Licensing Agreement February 09, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Isavuconazonium Sulfate,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : $226.0 million
Deal Type : Licensing Agreement
Basilea Receives Milestone Payment for Strong Cresemba Sales in Asia Pacific and China
Details : Cresemba (Isavuconazonium Sulfate) is a small molecule drug, which is currently being evaluated in Approved FDF clinical studies for the treatment of invasive pulmonary aspergillosis.
Product Name : Cresemba
Product Type : Miscellaneous
Upfront Cash : $3.0 million
February 09, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Pfizer has Asia Pacific and China rights for Cresemba (isavuconazole), an intravenous and oral azole antifungal.
Lead Product(s): Isavuconazonium Sulfate,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Cresemba
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Pfizer Inc
Deal Size: $226.0 million Upfront Cash: $3.0 million
Deal Type: Licensing Agreement June 05, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Isavuconazonium Sulfate,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : $226.0 million
Deal Type : Licensing Agreement
Strong Cresemba Sales Performance in Asia Pacific and China Triggers Milestone Payment
Details : Pfizer has Asia Pacific and China rights for Cresemba (isavuconazole), an intravenous and oral azole antifungal.
Product Name : Cresemba
Product Type : Miscellaneous
Upfront Cash : $3.0 million
June 05, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Cresemba, with the active ingredient isavuconazonium sulfate, is an intravenous (i.v.) and oral azole antifungal. Cresemba is marketed in more than 70 countries.
Lead Product(s): Isavuconazonium Sulfate,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Cresemba
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Asahi Kasei Pharma
Deal Size: $68.6 million Upfront Cash: $7.1 million
Deal Type: Licensing Agreement April 24, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Isavuconazonium Sulfate,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Asahi Kasei Pharma
Deal Size : $68.6 million
Deal Type : Licensing Agreement
Cresemba Sales in Japan Trigger Second Milestone Payment to Basilea
Details : Cresemba, with the active ingredient isavuconazonium sulfate, is an intravenous (i.v.) and oral azole antifungal. Cresemba is marketed in more than 70 countries.
Product Name : Cresemba
Product Type : Miscellaneous
Upfront Cash : $7.1 million
April 24, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Continued strong sales performance of Cresemba® (isavuconazole), an azole antifungal for invasive aspergillosis and mucormycosis, by its license partner Pfizer triggered milestone payment.
Lead Product(s): Isavuconazonium Sulfate,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Cresemba
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Pfizer Inc
Deal Size: $226.0 million Upfront Cash: $3.0 million
Deal Type: Licensing Agreement March 14, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Isavuconazonium Sulfate,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : $226.0 million
Deal Type : Licensing Agreement
Strong Cresemba Sales in Asia Trigger Milestone Payment to Basilea
Details : Continued strong sales performance of Cresemba® (isavuconazole), an azole antifungal for invasive aspergillosis and mucormycosis, by its license partner Pfizer triggered milestone payment.
Product Name : Cresemba
Product Type : Miscellaneous
Upfront Cash : $3.0 million
March 14, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Under the terms of the license agreement, Asahi Kasei Pharma is granted an exclusive license to develop and commercialize Cresemba (isavuconazole) in Japan.
Lead Product(s): Isavuconazonium Sulfate,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Cresemba
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Asahi Kasei Pharma
Deal Size: $68.0 million Upfront Cash: $7.19 million
Deal Type: Licensing Agreement February 05, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Isavuconazonium Sulfate,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Asahi Kasei Pharma
Deal Size : $68.0 million
Deal Type : Licensing Agreement
Cresemba's Japan Launch Triggers Sales Milestone for Basilea
Details : Under the terms of the license agreement, Asahi Kasei Pharma is granted an exclusive license to develop and commercialize Cresemba (isavuconazole) in Japan.
Product Name : Cresemba
Product Type : Miscellaneous
Upfront Cash : $7.19 million
February 05, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
AVIR has license in Canada for Cresemba (isavuconazole sulfate), approved for use in adults and pediatrics from 1 year up to 18 years for invasive aspergillosis and invasive mucormycosis.
Lead Product(s): Isavuconazonium Sulfate,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Cresemba
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Avir Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 28, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Isavuconazonium Sulfate,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Avir Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Strong Sales Growth for Cresemba and Zevtera Trigger Further Milestone Payments to Basilea
Details : AVIR has license in Canada for Cresemba (isavuconazole sulfate), approved for use in adults and pediatrics from 1 year up to 18 years for invasive aspergillosis and invasive mucormycosis.
Product Name : Cresemba
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 28, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Cresemba (isavuconazonium sulfate) is the prodrug of isavuconazole which is an azole antifungal indicated for the treatment of invasive aspergillosis and invasive mucormycosis.
Lead Product(s): Isavuconazonium Sulfate,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Cresemba
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Pfizer Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 10, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Isavuconazonium Sulfate,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Strong Cresemba® Sales in Asia Trigger Milestone Payment to Basilea
Details : Cresemba (isavuconazonium sulfate) is the prodrug of isavuconazole which is an azole antifungal indicated for the treatment of invasive aspergillosis and invasive mucormycosis.
Product Name : Cresemba
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 10, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
FDA approves expanded use of Cresemba® (isavuconazonium sulfate), an ergosterol inhibitor, in pediatric patients 1 year of age and older with invasive aspergillosis and invasive mucormycosis.
Lead Product(s): Isavuconazonium Sulfate,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Cresemba
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 27, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Isavuconazonium Sulfate,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
European Commission Approves Pediatric Use of Cresemba®, Triggers CHF 10M Milestone
Details : FDA approves expanded use of Cresemba® (isavuconazonium sulfate), an ergosterol inhibitor, in pediatric patients 1 year of age and older with invasive aspergillosis and invasive mucormycosis.
Product Name : Cresemba
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 27, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Cresemba (isavuconazonium sulfate) is the prodrug of isavuconazole which is an azole antifungal indicated for the treatment of invasive aspergillosis and invasive mucormycosis.
Lead Product(s): Isavuconazonium Sulfate,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Cresemba
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 11, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Isavuconazonium Sulfate,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Grants Orphan Drug and Pediatric Exclusivities for CRESEMBA in Pediatric Aspergillosis
Details : Cresemba (isavuconazonium sulfate) is the prodrug of isavuconazole which is an azole antifungal indicated for the treatment of invasive aspergillosis and invasive mucormycosis.
Product Name : Cresemba
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 11, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Knight will commercialize Cresemba (isavuconazole sulfate) in Latin America, an azole antifungal for treating adult patients with invasive aspergillosis, licensed for regional distribution.
Lead Product(s): Isavuconazonium Sulfate,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Cresemba
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Knight Therapeutics
Deal Size: Undisclosed Upfront Cash: $11.2 million
Deal Type: Licensing Agreement January 19, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Isavuconazonium Sulfate,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Knight Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Cresemba® Sales in Latin America Trigger First Sales Milestone Payment to Basilea
Details : Knight will commercialize Cresemba (isavuconazole sulfate) in Latin America, an azole antifungal for treating adult patients with invasive aspergillosis, licensed for regional distribution.
Product Name : Cresemba
Product Type : Miscellaneous
Upfront Cash : $11.2 million
January 19, 2024

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Global Sales Information
Market Place
Reply
10 Jan 2026
Reply
03 Nov 2022
Reply
30 Jun 2021
Reply
24 Apr 2021
Reply
23 Dec 2020
Reply
31 Aug 2020
Reply
11 Jun 2020
Reply
22 Oct 2019
Reply
24 Jul 2019
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
29
PharmaCompass offers a list of Isavuconazonium Sulfate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Isavuconazonium Sulfate manufacturer or Isavuconazonium Sulfate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Isavuconazonium Sulfate manufacturer or Isavuconazonium Sulfate supplier.
A Isavuconazole manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Isavuconazole, including repackagers and relabelers. The FDA regulates Isavuconazole manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Isavuconazole API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Isavuconazole manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Isavuconazole supplier is an individual or a company that provides Isavuconazole active pharmaceutical ingredient (API) or Isavuconazole finished formulations upon request. The Isavuconazole suppliers may include Isavuconazole API manufacturers, exporters, distributors and traders.
click here to find a list of Isavuconazole suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Isavuconazole DMF (Drug Master File) is a document detailing the whole manufacturing process of Isavuconazole active pharmaceutical ingredient (API) in detail. Different forms of Isavuconazole DMFs exist exist since differing nations have different regulations, such as Isavuconazole USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Isavuconazole DMF submitted to regulatory agencies in the US is known as a USDMF. Isavuconazole USDMF includes data on Isavuconazole's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Isavuconazole USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Isavuconazole suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Isavuconazole Drug Master File in Korea (Isavuconazole KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Isavuconazole. The MFDS reviews the Isavuconazole KDMF as part of the drug registration process and uses the information provided in the Isavuconazole KDMF to evaluate the safety and efficacy of the drug.
After submitting a Isavuconazole KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Isavuconazole API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Isavuconazole suppliers with KDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Isavuconazole as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Isavuconazole API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Isavuconazole as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Isavuconazole and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Isavuconazole NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Isavuconazole suppliers with NDC on PharmaCompass.
Isavuconazole Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Isavuconazole GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Isavuconazole GMP manufacturer or Isavuconazole GMP API supplier for your needs.
A Isavuconazole CoA (Certificate of Analysis) is a formal document that attests to Isavuconazole's compliance with Isavuconazole specifications and serves as a tool for batch-level quality control.
Isavuconazole CoA mostly includes findings from lab analyses of a specific batch. For each Isavuconazole CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Isavuconazole may be tested according to a variety of international standards, such as European Pharmacopoeia (Isavuconazole EP), Isavuconazole JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Isavuconazole USP).